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sub- locations in Kenya where hundred community health workers were trained 
on community based referral and counter referral model and issued with referral 
tools. Each was assigned 25 households, instructed to regularly visit them in order 
to identify sick persons counsel and refer them to link hospitals. One hundred vil-
lages comprising 2209 households with a population of 11,000 people were covered 
where the counter referral model was implemented. Results: Three hundred and 
twenty two sick persons were identified, counseled and referred to the two link 
health facilities by one hundred community health workers who covered one hun-
dred villages. It was further shown that 82% (263/322) arrived in the referral health 
facilities with referral slips on the same day, 5% (15/322) second day, 6% (20/322) 
third day and over while 7% (24/322) did not arrive in the hospitals. ConClusions: 
It was observed that community health workers regularly visited households. This 
observation is consistent with findings of previous similar studies. Only about less 
than a third of all the referrals did not arrive the link referral hospital the first day. 
It is therefore concluded that community health workers are a critical link between 
the households and primary health care facilities. They are likely to identify com-
mon illnesses during routine household visitation, counsel and refer sick persons 
to health facilities for care.
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objeCtives: A core outcome set (COS) is a standardised set of outcomes which 
should be measured and reported, as a minimum, in all effectiveness trials for a 
specific health area. This will allow results to be compared, contrasted and com-
bined as appropriate, as well as ensuring that all trials contribute usable informa-
tion. The aim of this review was to identify studies which sought to determine 
which outcomes or domains to measure in all clinical trials in a specific condition, 
and to describe the methodological techniques used in these studies. Methods: 
We developed a multi-faceted search strategy for electronic databases (MEDLINE, 
SCOPUS, and Cochrane Methodology Register). We included studies which sought 
to determine which outcomes/domains to measure in all clinical trials in a specific 
condition. Results: 198 studies (250 reports) were included in the review. Studies 
covered various areas of health, most commonly cancer, rheumatology, neurology, 
heart and circulation, and dentistry and oral health. A variety of methods have been 
used to develop COS, including semi-structured discussion, unstructured group 
discussion, the Delphi Technique, Consensus Development Conference, surveys and 
Nominal Group Technique. The most common groups involved were clinical experts 
and non-clinical research experts. Thirty-one (16%) studies reported that the public 
had been involved in the process. The geographic locations of participants were pre-
dominantly North America (n= 164; 83%) and Europe (n= 150; 76%). ConClusions: 
This review has brought together the existing research in a single place. COS will 
increase the efficiency and value of the research process and make it easier for 
people to make well-informed decisions about health care. Design of new trials 
will be simplified, risk of measuring inappropriate outcomes reduced, and selec-
tive reporting of outcomes less likely. We have highlighted future areas of research, 
including the need for methodological guidance for COS development and better 
reporting of COS studies.
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objeCtives: Increasingly, patients are becoming more active contributors to 
research. The purpose of this survey was to understand the experience and expec-
tations of patient organizations (POs) with clinical research and patient reported 
outcomes. Methods: An online survey was conducted in English language during 
May 2014 among 40 participants of a global cross disease patient forum. The infor-
mation was used to provide background regarding patients as active contributors in 
clinical research. The participants represent a broad range of disease specific and 
general patient organizations from various countries including USA, European coun-
tries, Asia, Latina America, Middle East and Australia. Results: The most important 
deficiencies of current clinical research practice were described as a lack of patient 
friendly reporting, incomplete reporting and a lack of patient involvement in the 
study design. Over the half of respondents stated that clinical trials are conducted 
in a way that does not yield information relevant to the patients. Active involvement 
in clinical trials was specified through 79 different expectations which fell into 7 
categories: (1) Accessibility of new medicines (2) More representative patient selec-
tion for studies (3) Transparent conduct of the study (4) Better information on safety 
and risks to participants (5) Active versus passive role of patients (6) Contribution 
to innovation (7) Improved result reporting; especially to patients. One third of the 
respondents have already been actively involved in clinical research and felt that this 
was a mostly positive experience. Globally, patients and patient organizations are 
becoming increasingly involved in clinical research through multiple formal or infor-
mal routes of engagement. ConClusions: Patients should be better represented in 
clinical research and consulted for patient relevant study aspects in order to provide 
information of greater relevance to patients in their own therapeutic decisions.
PHP184
drug rePurPosing as an eFFiCient strategy in drug develoPment – 
examPle oF Cns area
Toumi M.1, Murteira S.2, Caban A.3, Kornfeld A.4
1University Aix-Marseille, Marseille, France, 2Lundbeck Japan KK, Tokoyo, Japan, 3Creative-
Ceutical, Paris, France, 4Creativ-Ceutical, Paris, France
objeCtives: Traditionally, drug repurposing has been considered as a cost-effective 
and a reduced-risk strategy for developing new drugs. Currently little is known and 
documented regarding efficiency of repositioning strategies in drug development. 
The objective of this article is to assess the meaning of this process with focus on 
CNS area. We aim to identify the repositioning strategies that conducted to the 
discovery and development of new CNS products as well as identify the source and 
target indication and development status. Methods: In order to identify repur-
posing cases that target CNS, an extensive research was performed. It included a 
literature review as well as search of websites of organizations engaged in promot-
ing and development of drug repurposing. Cases were extracted from the source 
material. For each molecule, its initial and target indication as well as development 
status was recorded. Each case was classified by type of repurposing strategy (repo-
sitioning, reformulation or both). Results: 109 source products were identified. 
They were repositioned 183 times. About one third of the source products have 
been repositioned more than one time. Half of new indications was approved. The 
majority of cases were repositioned while only 10 were reformulated and 16 were 
reformulated and repositioned at the same time. The highest number of repurposed 
molecules was originating from CNS therapeutic area (67 molecules targeted 127 
indications). Among new therapeutic indications alcohol / opioid / drug dependence 
was targeted most often (20 repositions). Regarding repositions within CNS area, 
Schizophrenia, Epilepsy and Depression were the richest sources of repositioned 
drugs with 10 and more products each. ConClusions: Drug repurposing in CNS is 
an efficient and currently very active drug development strategy, exemplified by the 
considerable amount of new indications that have been found via this strategy, with 
approximately half of the target indications being currently under development.
PHP185
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objeCtives: Evidence to ensure cost-effective purchasing of services are an 
important pre-requisite for ensuring financial sustainability of health systems. 
The Research Agenda for Health Economic Evaluation project aims to map out the 
economic evidence available for the treatment of the 10 highest burden conditions 
in the European Union and identify evidence gaps. Methods:  The 10 highest 
burden diseases are selected by Disability Adjusted Life Years (DALYs) based on 
the Global Burden of Disease study for Europe (Ischemic Heart Disease, Low Back 
Pain, Stroke, Major Depressive Disorder, Lung Cancer, Falls, COPD, Diabetes, Other 
musculoskeletal, Neck pain). Clinical pathways are generated for these conditions by 
merging published clinical guidelines from public and professional bodies. Economic 
(cost-benefit and cost-effectiveness) evidence indexed by MEDLINE is stratified by 
treatment pathways to identify evidence gaps. Existing reviews are analysed to 
assess coverage of primary evidence. Results: Results are presented for diabetes: 
1,208 articles were retrieved from MEDLINE, of which 315 mapped to the treatment 
pathway. Most evidence was published after 2000. 74 reviews were identified, of 
which 24 were published between 2009-13. Volume of economic studies for each 
treatment ranged from 0 to 39 studies. The most intensively studied were diabetic 
retinopathy (n= 39), foot ulcers (n= 34) and renal disease (n= 31). Areas with no eco-
nomic evidence included non-pharmacological blood pressure and dyslipidemia 
control. In some cases economic evidence was available, but no recent reviews of 
the evidence were identified (eg. islet or pancreas transplantation, diabetic neu-
ropathy, interventions for weight loss). ConClusions: Economic evidence was 
available for the majority of treatment modalities for diabetes, however for several 
treatments no studies were identified. Importantly, reviews were not identified 
for several treatments where economic evidence was available. Lack of economic 
evidence prevents cost-effective commissioning, and lack of reviews of evidence 
may be a further barrier to translation.
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objeCtives: China and the United States have approved massive health care 
reforms seeking to increase access to affordable health care services. Both coun-
tries employed a composite of government programs and private enterprises 
designed to improve efficiencies in their health care markets. This study com-
pares the results of these health care reforms so far, explores the longer-term 
prognoses and considers how lessons learnt can inform health care reform else-
where. Methods: In the U.S., 80 MCOs and 240 physicians were surveyed about 
their participation in reform programs. Quarterly data on the uninsured and health 
care cost trend data were also assessed. In China, 670 patients were surveyed 
regarding their access to a health care provider. Results: Early returns show 
mixed results that stem from policy decisions inherent in the original programs 
as well as from national political considerations. Overall, both the U.S. and China 
health care reforms are enjoying success but have shortcomings. In the U.S, parti-
sanship, technology issues, and implementation uncertainties have undermined 
the reform legislation. However, the nation’s uninsured rate declined from 17.1% 
in Q4 2013 to 13.4% in Q2 2014, and the health care cost trend has fallen. Moreover, 
the predicted spike in emergency room utilization has not yet appeared. In China, 
the percentage of citizens with coverage increased from 30% in 2003 to 95% in 2011, 
while patients’ share of out-of-pocket costs fell. However, improvement is felt less 
in rural regions and demand for services is increasing. Consequently, Chinese 
citizens still have difficulty accessing health care providers, which, combined 
with inadequate reimbursement rates, means health care in China remains sub-
optimal. ConClusions: Together with early coverage statistics, responses from 
both the U. S. and China to challenges in their respective health care reform efforts 
indicate that long-term success is achievable. Their experiences underscore the 
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need for political unity, substantial financial investments, and adaptability when 
faced with obstacles and suboptimal results.
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objeCtives: An increasing range of online education is available to those working 
in the field of pharmaco-economics and Health Technology Assessment (HTA). The 
aim of this study was to explore the market for free online education in HTA and to 
assess the practicalities of delivering a free, interactive short-course. Methods: 
We delivered a 5-week online course at the end of 2013 following the princi-
ples of the Massive Open Online Course (MOOC) approach: the HTA MOOC. The 
programme covered the basics of HTA: What it is; how new technologies are 
identified; how they are evaluated; the principal means of assessing clinical and 
cost-effectiveness; and how HTA is used within different health systems to inform 
reimbursement decisions. The course was provided through the Coursesites, a free, 
open-access, education platform. Materials were adapted from an existing online 
MSc programme. Descriptive statistics of participants were recorded and a survey 
conducted of participants’ experiences. Results: 2039 individuals registered for 
the HTA MOOC, of which 1508 completed a voluntary survey giving basic socio-
demographic data about themselves. Participants were from Europe (55%), Asia 
(16%) and North America (13%) and accessed the MOOC to gain knowledge about 
the subject (78%), and specifically for career development (56%). 531/2039 (26%) 
of those registered in Week 1 completed the MOOC (i.e. submitted all required 
weekly assessments by the end of Week 5), compared to an average of 5-6% for 
MOOCs generally [THES 2013]. Students reported the principal strength of the 
programme to be the quality and usefulness of the learning materials, and the 
principal issue to be time required (workload was considered by some to exceed 
the 4-5 hours/week intended). ConClusions: The MOOC approach offers scope 
for delivering flexible, effective and accessible education to small or large inter-
national cohorts of professionals, patients and providers working within HTA and 
pharmaco-economics.
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objeCtives: The objective of this study was to survey the pharmacy schools in 
Brazil to determine the extent of education in pharmacoeconomics offered during 
the school year 2012-2013. Methods: A questionnaire based on previous studies 
was developed. This was emailed to 55 pharmacy schools in Brazil during October 
and December 2013. The schools were selected from the Ministry of Education 
website. Public and private University schools (only those that have high concepts 
in the National Examination Performance of Students) were included. In addition, 
a search was made in the database directories of research groups from National 
Council for Scientific and Technological Development (CNPq). Results: Of the 55 
questionnaires sent, 16 were returned (29%). Only two schools do not address the 
education of pharmacoeconomics in any moment. Most of schools address some 
concepts in different subjects (8 hours). Five schools have formal courses that 
teach only pharmacoeconomics and health technology assessment (over 30 hours). 
All agree that the education of pharmacoeconomics is important and ten schools 
believe that very few hours are devoted to the teaching pharmacoeconomics at 
his university. In search of directories of research groups 23 groups that develop 
research in the area of pharmacoeconomics in Brazil were found. ConClusions: 
There is a large deficit in the availability of courses pharmacoeconomics in Brazil 
at both the undergraduate and graduate. There is a great opportunity for expe-
rienced individuals to fill this gap. Provide an education in pharmacoeconomics 
for pharmacy students is especially important in the context of evidence-based 
decisions and when health issues and allocation of scarce resources is a priority 
for Brazil.
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objeCtives: Post-hoc subgroup analyses are still used in clinical trials of medi-
cal technologies to identify patient populations in whom greatest benefits can 
be achieved, despite this being derided as an analytical approach. Indeed, using 
such an approach, aspirin has been shown to be ineffective versus placebo in 
acute myocardial infarction patients born under the star signs of Libra and Gemini 
(ISIS-2, 1988, Lancet) and endarterectomy is only efficacious in treating sympto-
matic stenosis patients born on a Monday, Wednesday, or Friday (ECST group, 1998, 
Lancet). This research aimed to determine what effect the name of a drug has 
on the National Institute of Health and Care Excellence (NICE) appraisal process 
by applying a post-hoc analysis that compares the rates of acceptance by the 
first letter of the drug or technology name using a Chi-squared test. Methods: 
All final appraisal determinations resulting from Single Technology Appraisal 
(STA) or Multiple Technology Appraisal (MTA) processes were identified up 
to April 2014 from which the first letter of the generic name and the decision 
were extracted. Results: 481 appraisals were identified, 371 (77%) of which 
were approved (defined as ‘recommended’ or ‘optimised’), spanning all letters 
of the alphabet except J, K, W, X, and Y. The lowest approval rates by letter were 
for B (64%, 14/22) and S (69%, 18/26). Drugs beginning with a B or S were sig-
nificantly less likely to be approved than drugs beginning with any other letter 
(p= 0.0072). ConClusions: Based on this ‘NICE post-hoc B/S analysis,’ manufac-
turers should consider lobbying the World Health Organization to give their new 
pharmaceuticals International Nonproprietary Names beginning with ‘B’ or ‘S’ 
to optimise success rates in the NICE appraisal process. Alternatively, regulators 
and HTA bodies should continue to view efficacy claims on the basis of post-hoc 
sub-group analyses with great scepticism.
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objeCtives: Evaluation of the impact of children stories on promotion 
of the knowledge and behavior of 4th stage elementary students about 
rational use of medicines in the Kermanshah elementary schools. Methods: 
64 elementary schools were selected in Kermanshah province of Iran. The 
schools were categorized into 3 groups (rich, medium and poor level) based on 
their students’ economic level. Both boys and girls were involved. Two checklists 
were designed in order to evaluate students’ knowledge and behavior before 
and after the intervention. A story book which was published by National 
Committee of Rational Drug Use (RUD) conveyed to the students as the inter-
vention. Results:  The correlation between pre and post intervention and the 
schools economic levels and the gender of students were obtained. The knowl-
edge change rates were 21.83%, 22.28% and 17.40% for rich, medium and poor 
schools respectively. The change rate for girls was greater in comparison to 
that of boys. ConClusions: It is concluded that children stories as an educa-
tional intervention causes valuable positive changes on students’ knowledge 
and behavior regarding hygiene and medicine. Implementing such interven-
tions among children, result in promoting rational use of medicines in future 
of the society.
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objeCtives: Despite high-performance infrastructures and recognized 
expertise, Clinical trials (CT) are declining in France. Health Professionals 
deplore the burdens of the French administration that leads to a real concern 
regarding the international scientific competition. In addition patients are reluc-
tant to participate in CT especially after the benfluorex scandale. Methods: One 
of the witnesses of the competitiveness of France in CT is the activities among 
Clinical Investigation Centers (CIC). These are plateforms fully dedicated to clini-
cal and scientific research acting as an interface between INSERM units (Public 
National Institut of Scientific Research) and CHU (University Hospital). Results: 
There are 54 CIC in France. They have been created between 1992 and 2009. CICs 
are located in university hospitals (CHU) dessiminated in the most important 
regions of the country. The specific needs of CHU and researchers have led to 
implement several types of CICs: multi-topics (24 CIC-P), Clinical Epidemiology 
(9 CIC-EC), integrated in biotherapy (11 CIC-BT) and technological innovations (8 
CIC-IT). During the last quadrennium, CIC-P supervised about 1000 protocols, of 
which 2/3 were therapeutic and 1/3 on physiopathology. 25% of protocols con-
ducted in CIC-P were translational in collaboration with INSERM units, 20% were 
for rare diseases, 35% were funded by industry and 36% by the PHRC (Academic 
funding). The AP-HP (Academic Hospitals of Paris Area) is the major sponsor in 
France and one of the first in Europe, with 500 clinical trials enrolling more than 
17,000 patients in 2010. Despite this development, the number of CT submis-
sions to ANSM (French Regulatory Agency) decreased from 1,000 in 2008 to 895 in 
2012. ANSM approuved 705 protocols in 2012 versus 790 in 2008. ConClusions: 
Despite appropriate structures and willingness to encourage scientific produc-
tion, clinical trails remain underexploited due to different causes which need to 
be deeply evaluated.
HealtH Care use & PoliCy studies – Health technology assessment  
Programs
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objeCtives: In March, the National Institute for Health and Care Excellence (NICE) 
revealed their plans to implement Value Based Assessment (VBA) in their Technology 
Appraisal process: VBA will replace NICE’s end-of-life criteria. Instead wider soci-
etal impact (WSI) and burden of illness (BOI) will be systematically included in the 
assessment through absolute and proportional Quality Adjusted Life Year (QALY) 
shortfall. However, it is unclear whether these elements will impact NICE’s recom-
mendations. Methods: The BOI and WSI for the 26 examples provided by NICE 
was compared with an average displaced treatment in the NHS. Assuming that both 
elements were weighted equally, an average QALY shortfall rating was calculated. 
This was then transformed into a hypothetical willingness to pay (WTP) threshold 
ranging from £20,000 for the drug with the lowest rating to £50,000 per QALY for 
the drug with the highest rating. The hypothetical WTP was compared with the 
most plausible ICER and recommendation from NICE. Results: Multiple Sclerosis, 
rheumatoid and psoriatic arthritis, as well as oncology indications were associated 
with a high BOI/WSI. Six of the 26 examples had higher most plausible ICERs than 
the estimated threshold. Two of these six were still recommended using end-of-
life criteria (metastatic melanoma and mCRPC), whereas the remainder were not 
recommended by NICE. Three of the 26 examples had ICERs below the estimated 
WTP threshold but higher than £30,000, and were still recommended. All of these 
recommendations mentioned additional value elements such as innovation, end-of-
